Press release from Business Wire India
Source: Neuland Laboratories
Thursday, August 27, 2009 04:38 PM IST (11:08 AM GMT)
Editors: General: Consumer interest; Business: Advertising, PR & marketing, Business services, Healthcare, biotechnology & pharmaceutical; Healthcare
Neuland Laboratories Announces Commercial Production of Peptides
High Potent APIs to be the Growth Driver
Hyderabad, Andhra Pradesh, India, Thursday, August 27, 2009 — (Business Wire India) — — Commissions a new facility for the cGMP manufacturing of High Potent APIs (HAPIs)
— Commences work on Vitamin-D2 analogs, compounds for oncology and nucleosides besides Peptides
— HAPI’s poised to contribute to 20% of the bottom-line over the next 2-3 years
Neuland Laboratories Limited, a reliable global provider of APIs and other essential drug discovery and development support services today announced successfully commencement of manufacturing of peptides blocks by successfully commercializing the production of Fmoc Pseudoproline Dipeptides and other building blocks in India and the US subsidiary.
In the initial phase the company will target the US and Europe markets. Developing markets will follow in the next phase. Neuland’s quality of products is superior with attractive pricing and it is poised to penetrate into this peptide synthesis market.
Dr. D R Rao, Chairman & Managing Director, Neuland Laboratories said, “We are committed to making Neuland Laboratories the premier peptide service facility in the world, and becoming the preferred choice for the world peptide community. Our foray into peptides is a reflection of our focused plans of being profitable and giving more value to our investors, besides growing our client base.”
He added, “Over the next two years Neuland will integrate the peptide value chain by leveraging on the existing expertise in API and contract manufacturing, thus creating a niche opportunity for itself in this segment. The company will develop in-house process capabilities for commercial manufacture of peptides”
Neuland also announced its foray and focus into High potent APIs (HAPIs) thus making another stride towards bringing more value and synergy to the company’s contract research and generic APIs business. The move into this niche market segment reinforces Neuland’s intent to focus on opportunities that require higher barriers to entry, while also leveraging the company’s existing intellectual capital and regulatory strength.
The company has commissioned a new facility for manufacturing of High Potent APIs (HAPIs). The company has also reinforced its R&D resources to support its focus on development of HAPIs.
Neuland has identified and initiated the work in the high growth areas of Vitamin-D analogs, Oncology Nucleosides and Peptides among the other HAPIs where it can capitalize its strengths in chemistry, contract research and manufacturing expertise while projecting the company’s business philosophy of quality and on time delivery.
Mr. Sucheth Rao Davuluri, Chief Executive Officer (CEO), Neuland Laboratories Limited said “Advances in drug delivery technologies are opening up avenues in High potent APIs (HAPIs), peptides and other niche market segments like Vitamin D analogs. Neuland sees this as a potential area for high growth, which is a synergy with both our contract research and API business. Neuland has also commissioned a new facility for the cGMP manufacturing of High Potent APIs (HAPIs) and also adding the R&D resources to support development of HAPIs.”
Neuland will continue to increase its product range by adding approximately 20 new products this year to its existing portfolio of APIs that will help sustain and grow the core capabilities of the company.
Peptides are smaller versions of proteins, and they play a key role in regulating body functions such as the release of hormones, the regulation of blood sugar levels, bone metabolism and various neurological processes. They are
polymers made up of the naturally occurring amino acids. Peptide drugs are developed as novel therapies for cancer, pain treatment, viral infections, diabetes and a host of endocrine and neurological disorders.
The current market for peptide drugs is in the $5 billion to $10 billion ranges, and peptides are expected to be the “next generation of wonder drugs”.
About Neuland Laboratories Ltd:
Neuland Laboratories ltd is a well-established, reliable global provider of API and other essential drug discovery and development services. Neuland manufactures for over 700 customers located in 85 countries. The company’s customers include the top 30-pharma companies in Europe and USA.
The company’s customers include the top 30-pharma companies in Europe and USA. Neuland with its experience in two decades of manufacturing has a team of scientists working for bringing complex molecules with efficient processes to market, develop non-infringing processes, develop cost effective routes, reduce impurities levels by better process understanding & reduce effluent generation.
Neuland’s product portfolio spans a mix of APIs across 8 major therapeutic categories. Neuland Labs has two Research & Development facilities on the outskirts of Hyderabad. Neuland Labs key focus on Contract Research & Development Services Contract Chemistry-based services closely related to their API manufacturing business. These include Medicinal Chemistry (Discovery Support), Process Development, Drug Development Support, Analytical R&D Synthesis Laboratories, Analytical Laboratories, Kilo Laboratories and a Hydrogenation Laboratory, which are equipped with best-in-class equipments.
Besides its core business of API manufacturing, Neuland is currently focused on the two new businesses –
1. Contract Research and Manufacturing services – this is a Chemistry-based services closely related to the API manufacturing business. The facilities are housed in the Neuland R&D center. For this business, Neuland is looking at a diverse range of therapeutic areas (excluding oncology drugs), mostly for customers based in North America and Europe.
2. Clinical Research services- The Company has incorporated Cato research Neuland India for this, a JV with Cato Research Inc., to conduct clinical trials (Ph 2 and Ph 3) in India for Cato Research worldwide. The therapeutics areas and countries would be diverse, in line with Cato Research’s operations.
Kavita K Bhaskaran, Sampark Public Relations, +91 9987355009, [email protected]
CONSUMER, MARKETING, BUSINESS SERVICES, HEALTHCARE, HEALTHCARE
If you wish to change your Business Wire India selection please click on this link http://www.businesswireindia.com/media/news.asp and use your personal username and password to login.
Submit your press release at http://www.businesswireindia.com